Multivalent anti-CCR5 ribozymes for stem cell-based HIV type 1 gene therapy

AIDS Research and Human Retroviruses

Volumn 17, Issue 5, 2001, Pages 385-399

  Bai, J ^a   Rossi, J ^b   Akkina, R ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; REV PROTEIN; RIBOZYME; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VECTOR; BETA CHEMOKINE;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; TRANSGENE; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; MACROPHAGE; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MUTATION; PHYSIOLOGY; SEQUENCE ALIGNMENT; VIROLOGY;

CELL LINE; CHEMOKINES, CC; DOWN-REGULATION; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; MACROPHAGES; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTORS, CCR5; RNA, CATALYTIC; SEQUENCE ALIGNMENT; TRANSDUCTION, GENETIC;

EID: 0035794261     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201750102427     Document Type: Article

References (73)

1. Global program struggles to stem the flood of new cases
2. AIDS as a zoonosis: Scientific and public health implications
3. Toward HIV eradication or remission: The tasks ahead
4. Latent infection of CD4 T cells provides a mechanism for life-long persistence of HIV-1 infection, even in patients on effective combination therapy
5. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
6. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
7. HIV-1: Gambling on the evolution of drug resistance
8. HIV treatment failure: Testing for HIV resistance in clinical practice
9. Viral envelope fails to deliver
10. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
11. Progress in the development of an HIV vaccine
12. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions
13. Viral dynamics in human immunodeficiency virus type 1 infection
14. New developments in the biology and treatment of HIV
15. Down regulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimerical transcripts
16. + monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA
17. + hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long term culture
18. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS
19. Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection
20. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication
21. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication
22. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins
23. Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model
24. Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector
25. Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase
26. A new classification for HIV-1
27. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
28. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression
29. The HIV-1 envelope glycoproteins: Fusogenes, antigens, and immunogens
30. HIV-1 entry inhibitors: Evading the issue
31. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue
32. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytoctropic to T-cell tropic virus populations
33. HIV infection and dementia
34. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia
35. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression
36. Simple RNA enzymes with new and highly specific endoribonuclease activities
37. A small catalytic oligoribonucleotide
38. A novel ribozyme target site located in the HIV-1 nef open reading frame
39. Ribozyme gene therapy for HIV infection: Intracellular immunization of lymphocytes and CD34+ cells with an anti-HIV-1 ribozyme gene
40. In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1
41. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes
42. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: Comparison of RNA levels and viral inhibition
43. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo
44. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha
45. CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: Lack of association with mutations other than CCR5-Δ32
46. Structure and functional expression of the human macrophage inflammatory 1 alpha (MIP-1alpha)/RANTES receptor
47. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternate splicing of the carboxyl-terminal tails
48. Cloning and functional expression of a human eosinophil CC chemokine receptor
49. Improved retroviral vectors for gene transfer and expression
50. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells
51. Targeting of HIV-1 and SIV-infected cells by CD4-chemokine receptor pseudotypes
52. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells
53. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudo-typed with vesicular stomatitis virus envelope glycoprotein G
54. Molecular cloning analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G
55. Identification of a major co-receptor for primary isolates of HIV-1
56. Packaging system for rapid production of murine leukemia virus vectors with variable tropism
57. Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse
58. Limitations of a molecular clock applied to considerations of the origin of HIV-1
59. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms
60. Chemokines and HIV-1 second receptors: The therapeutic connection
61. Coreceptors: Implications for HIV pathogenesis and therapy
62. Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: Inhibition of the coreceptor function by DNA enzyme
63. A hammerhead ribozyme targeted to the human chemokine receptor CCR5
64. Val-heterodimeric maxizymes with high potential as gene-inactiviting agents: Simultaneous cleavage at two sites in HIV-1 tat mRNA in cultured cells
65. Importance of independence in ribozyme reactions: Kinetic behavior of trimmed and simply connected multiple ribozymes with potential activity against human immunodeficiency virus
66. HIV-1 infection in an individual homozygous for the CCR5 deletion allele
67. Susceptibility of in vitro stimulated PMBC to infection with NSI HIV-1 is associated with levels of CCR5 expression and β-chemokine production
68. Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5
69. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro
70. Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines
71. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection
72. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat